Navigation Links
PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
Date:2/9/2009

SAN DIEGO, Feb. 9 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced today that it has recently completed a collaboration with LigoCyte Pharmaceuticals, Inc. Under the collaborative agreement, PacificGMP produced master cell and baculovirus banks and will provide storage services under cGMP (current good manufacturing practices) standards for LigoCyte's norovirus vaccine program. Furthermore, PacificGMP conducted the services under an accelerated timeline.

"We are pleased that LigoCyte chose PacificGMP to produce the master cell and baculovirus banks that will be used to produce their next-generation, intra-muscular norovirus vaccine candidate," said Leigh N. Pierce, President of PacificGMP. "The timeline specified in this agreement further demonstrates the time saving advantages of single-use technology as we were able to quickly initiate this project in order to assist LigoCyte in maintaining its program schedule."

"Through their diligent efforts, PacificGMP demonstrated their GMP proficiency and allowed us to maintain our program timelines," said Bryan Steadman, Senior Director of CMC Operations for LigoCyte. "We appreciate PacificGMP's assistance in the development of our vaccine for norovirus infection, an illness that afflicts an estimated 23 million individuals in the U.S. annually, frequently resulting in serious medical consequences."

About PacificGMP

PacificGMP is a contract manufacturer and industry leader in single-use technology for development and manufacturing of biologics. Single-use technology eliminates the risk of cross-contamination, has fewer system requirements and significantly reduces the time required to initiate production. Benefits to clients include rapid project turnaround and the most cost effective solution in the industry. PacificGMP partners with drug developers by providing a range of cGMP and non-GMP services from cell line optimization, early process design, development, purification and scale-up, to preclinical and clinical manufacturing, aseptic filling, testing, analytical services and regulatory support. More information can be found by visiting the Company's web site at www.PacificGMP.com.

About LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals is a private biopharmaceutical company focused on the development of innovative vaccine products based on the company's proprietary virus-like particle platform technology. LigoCyte's lead candidate recently completed a Phase I clinical trial. The vaccine is being developed for the prevention of norovirus gastroenteritis, an illness that causes an estimated 64,000 hospitalizations and 900,000 clinical visits among children annually in the U.S, according to the CDC. LigoCyte also has a novel influenza vaccine in preclinical development that has, notably, demonstrated protection in ferrets across multiple influenza subtypes with a single VLP antigen. Incorporated in 1998, LigoCyte has 45 employees and is located in Bozeman, Montana. Please visit www.ligocyte.com for more information.

    Contact:

    PacificGMP
    Gary Pierce
    Chief Business Officer
    858-550-4094

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Leigh Pierce

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271


'/>"/>
SOURCE PacificGMP
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
2. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
3. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
4. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
5. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
6. Tigris Pharmaceuticals Files IND Application for GGTI-2418
7. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
8. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
9. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
11. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
Breaking Biology News(10 mins):